Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines

Ann Intern Med. 2025 Oct;178(10):1469-1477. doi: 10.7326/ANNALS-25-00706. Epub 2025 Aug 19.

Abstract

Description: Optimal transfusion strategies for patients with acute myocardial infarction (AMI) are uncertain. The aim of this guideline is to provide recommendations for red blood cell transfusion in patients with AMI.

Methods: These guidelines are based on evidence from randomized controlled trials of patients presenting with AMI and assigned to 2 different transfusion strategies (restrictive or liberal) based on hemoglobin concentrations or hematocrit levels before receipt of a transfusion. A meta-analysis of eligible trials was performed using Cochrane methods. The international panel followed GRADE (Grading of Recommendations Assessment, Development and Evaluation) methods to summarize evidence and formulate recommendations. This guideline's primary perspective is that of the patient, including medical, financial, and psychological effects, with secondary consideration of health care system issues, particularly conservation of the limited and costly blood supply.

Recommendation: For hospitalized patients with AMI, the panel suggests a liberal red cell transfusion strategy when the hemoglobin concentration is less than 10 g/dL (conditional recommendation, low-certainty evidence). A restrictive strategy of 7 to 8 g/dL may result in increased mortality in patients with AMI. The direction of the recommendation for the liberal strategy was based on the great importance of mortality for patients. The conditional recommendation was based on the low certainty of evidence and the competing consideration of blood supply conservation. Clinicians should adopt mitigation strategies to reduce potential adverse events associated with a liberal transfusion strategy, and all transfusion decisions should incorporate the clinical context rather than solely the hemoglobin concentration.

Publication types

  • Practice Guideline

MeSH terms

  • Erythrocyte Transfusion* / adverse effects
  • Erythrocyte Transfusion* / economics
  • Erythrocyte Transfusion* / methods
  • Hematocrit
  • Hemoglobins / analysis
  • Humans
  • Myocardial Infarction* / blood
  • Myocardial Infarction* / mortality
  • Myocardial Infarction* / therapy
  • Randomized Controlled Trials as Topic

Substances

  • Hemoglobins